Cantor Fitzgerald Forecasts Pfizer FY2026 Earnings

Pfizer Inc. (NYSE:PFE) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Pfizer in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post earnings of $3.10 per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $24.00 target price on the stock. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis.

A number of other brokerages have also weighed in on PFE. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Price Performance

Shares of PFE stock opened at $24.46 on Tuesday. Pfizer has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The firm has a market capitalization of $139.04 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock’s 50-day simple moving average is $22.96 and its 200-day simple moving average is $24.98.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tallon Kerry Patrick purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $509,000. Brighton Jones LLC raised its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. Strategic Financial Concepts LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $2,281,000. Finally, Vest Financial LLC raised its position in shares of Pfizer by 15.1% during the 4th quarter. Vest Financial LLC now owns 27,234 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 3,573 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.03%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.